RNAi delivered directly to the brain. The future of precision neuropsychiatry has arrived.
About Us
Cognigenics is developing iRNAi™, a precise, non-invasive, intranasal RNA interference platform that delivers programmable therapeutics directly to key areas of the brain to modulate the neural circuits underlying mood, memory, and cognition—supporting lasting brain health and cognitive function across the lifespan.
iRNAi™ will define the next generation of brain therapeutics.
By targeting underlying neural circuits directly, RNAi delivers unprecedented precision, potency, and durability—acting at the intracellular origin of disease while eliminating the costly side effects of systemic exposure. At Cognigenics, we are redefining how brain disorders are treated—enabling durable improvements in memory, emotional health, and cognition. The future of medicine is here.
Platform at a Glance
Using non-invasive intranasal delivery to bypass the blood–brain barrier, our RNAi platform enables precise, durable circuit-level modulation with minimal systemic exposure.
How It Works
Non-Invasive, Targeted Delivery of RNAi Advances in intranasal delivery enable non-invasive, direct access to the brain
Leveraging this approach, our RNAi platform bypasses the blood–brain barrier entirely, enabling preferential access to core limbic circuits and precise recalibration of memory and mood—delivering lasting cognitive and emotional benefits.
Precision Today. Prevention Tomorrow.
Delivering the right RNA medicine to the right brain circuit—by design
At Cognigenics, we believe the future of brain medicine lies in biological precision and non-systemic delivery. Just as precision oncology advanced by targeting defined pathways and structures, iRNAi™ is being built to precisely modulate specific brain circuits, structures, and cell types that underlie neurological and psychiatric disorders.
By combining circuit-, structure-, and cell-specific breakthroughs in RNA biology with advanced delivery and biomarker-guided development, we are building a platform that will move CNS care beyond broad, systemic drugs toward targeted, disease-modifying interventions — opening a clear path to earlier treatment and, ultimately, prevention.
Cognigenics Research Publications
The science behind intranasal genetic therapeutics for memory, anxiety, and neurological conditions.
- Genomic Psychiatry, Treatment with shRNA to knock down the 5-HT2a receptor improves memory →
- Nature, Translational Psychiatry, Intranasal delivery of shRNA to knockdown the 5HT-2a receptor enhances memory and alleviates anxiety →
- PNAS Nexus, Genetic modulation of the HTR2a gene reduces anxiety-related behavior in mice →
- Springer, Nature, Toward a new class of genetic therapeutics, Dean Radin et al. →
- Nature Research, Long-lasting genetic therapeutics for debilitating neurological conditions →
Leadership
World-class experts in neuroscience, genetics, and drug development united by a shared mission.
Regulatory Disclaimer
This product is currently under development and has not been approved for sale or distribution in the United States. It is not available for purchase or use and has not been evaluated by the U.S. Food and Drug Administration (FDA) for safety or efficacy. For informational purposes only.